Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 20, 2024 - Issue 1
Submit an article Journal homepage
1,656
Views
0
CrossRef citations to date
0
Altmetric
Novel Vaccines

A systematic review on malaria and dengue vaccines for the effective management of these mosquito borne diseases: Improving public health

Hind M. Al-Osaimia Department of Pharmacy Services Administration, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Kingdom of Saudi ArabiaView further author information
,
Mohammed Kananb Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, Kingdom of Saudi ArabiaCorrespondence[email protected]
View further author information
,
Lujain Marghlanic Department of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi ArabiaORCID Iconhttps://orcid.org/0009-0003-2114-8784View further author information
ORCID Icon,
Badria Al-Rowailid Pharmaceutical Services Department, Northern Area Armed Forces Hospital, King Khalid Military, Hafr Al Batin, Kingdom of Saudi ArabiaView further author information
,
Reem Albalawie Department of Medicine, Tabuk University, Tabuk, Kingdom of Saudi ArabiaORCID Iconhttps://orcid.org/0009-0007-4987-7638View further author information
ORCID Icon,
Abrar Saadf Pharmacy Department, Royal Commission Hospital, Yanbu, Kingdom of Saudi ArabiaORCID Iconhttps://orcid.org/0009-0009-3502-3118View further author information
ORCID Icon,
Saba Alasmarig Department of Clinical Pharmacy, King Khalid University, Jeddah, Kingdom of Saudi ArabiaView further author information
,
Khaled Althobaitih Department of Medicine, Taif University, Ta’if, Kingdom of Saudi ArabiaORCID Iconhttps://orcid.org/0009-0000-2171-1985View further author information
ORCID Icon,
Zainab Alhulailii Department of Clinical Pharmacy, Dammam Medical Complex, Dammam, Kingdom of Saudi ArabiaView further author information
,
Abeer Alanzij Department of Medicine, King Abdulaziz Hospital, Makkah, Kingdom of Saudi ArabiaORCID Iconhttps://orcid.org/0009-0005-1234-5641View further author information
ORCID Icon,
Rawan Alqarnik Department of Medicine and Surgery, King Khalid University, Abha, Kingdom of Saudi ArabiaView further author information
,
Razan Alsofiyanih Department of Medicine, Taif University, Ta’if, Kingdom of Saudi ArabiaView further author information
&
Reem Shrwanil Department of Clinical Pharmacy, Jazan University, Jazan, Kingdom of Saudi ArabiaView further author information
 show all
Article: 2337985 | Received 17 Feb 2024, Accepted 28 Mar 2024, Published online: 11 Apr 2024

References

  • Swei A, Couper LI, Coffey LL, Kapan D, Bennett S. Patterns, drivers, and challenges of vector-borne disease emergence. Vector-Borne Zoonotic Dis. 2020;20(3):159–16. doi:10.1089/vbz.2018.2432.
  • Petersen LR, Beard CB, Visser SN. Combatting the increasing threat of vector-borne disease in the United States with a national vector-borne disease prevention and control system. Am J Trop Med Hyg. 2019;100(2):242. doi:10.4269/ajtmh.18-0841.
  • Eder M, Cortes F, Teixeira de Siqueira Filha N, Araújo de França GV, Degroote S, Braga C, Ridde V, Turchi Martelli CM. Scoping review on vector-borne diseases in urban areas: transmission dynamics, vectorial capacity and co-infection. Infect Dis Poverty. 2018;7(1):1–24. doi:10.1186/s40249-018-0475-7.
  • Chala B, Hamde F. Emerging and re-emerging vector-borne infectious diseases and the challenges for control: a review. Front Public Health. 2021;9:715759. doi:10.3389/fpubh.2021.715759.
  • Chao C, Leone JL, Vigliano CA. Chagas disease: historic perspective. Biochim Biophys Acta (BBA)-Mol Basis Dis. 2020;1866(5):165689. doi:10.1016/j.bbadis.2020.165689.
  • Suk JE, Van Cangh T, Beaute J, Bartels C, Tsolova S, Pharris A, Ciotti M, Semenza JC. The interconnected and cross-border nature of risks posed by infectious diseases. Glob Health Action. 2014;7(1):25287. doi:10.3402/gha.v7.25287.
  • Golding N, Wilson AL, Moyes CL, Cano J, Pigott DM, Velayudhan R, Brooker SJ, Smith DL, Hay SI, Lindsay SW, et al. Integrating vector control across diseases. BMC Med. 2015;13(1):249. doi:10.1186/s12916-015-0491-4.
  • Wikel S. Ticks and tick-borne pathogens at the cutaneous interface: host defenses, tick countermeasures, and a suitable environment for pathogen establishment. Front Microbiol. 2013;4:337. doi:10.3389/fmicb.2013.00337.
  • Sachs J, Malaney P. The economic and social burden of malaria. Nature. 2002;415(6872):680–5. doi:10.1038/415680a.
  • O’Meara WP, Mangeni JN, Steketee R, Greenwood B. Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis. 2010;10(8):545–55. doi:10.1016/S1473-3099(10)70096-7.
  • Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7. doi:10.1038/nature12060.
  • Shepard DS, Undurraga EA, Halasa YA. Economic and disease burden of dengue in Southeast Asia. PLOS Negl Trop Dis. 2013;7(2):e2055. doi:10.1371/journal.pntd.0002055.
  • Semenza JC, Suk JE. Vector-borne diseases and climate change: a European perspective. FEMS Microbiol Lett. 2018;365(2):fnx244. doi:10.1093/femsle/fnx244.
  • Medlock JM, Leach SA. Effect of climate change on vector-borne disease risk in the UK. Lancet Infect Dis. 2015;15(6):721–30. doi:10.1016/S1473-3099(15)70091-5.
  • Tourapi C, Tsioutis C. Circular policy: a new approach to vector and vector-borne diseases’ management in line with the global vector control response (2017–2030). Trop Med Infect Dis. 2022;7(7):125. doi:10.3390/tropicalmed7070125.
  • Wilson AL, Courtenay O, Kelly-Hope LA, Scott TW, Takken W, Torr SJ, Lindsay SW. The importance of vector control for the control and elimination of vector-borne diseases. PLoS Negl Trop Dis. 2020;14(1):e0007831. doi:10.1371/journal.pntd.0007831.
  • Keiser J, Singer BH, Utzinger J. Reducing the burden of malaria in different eco-epidemiological settings with environmental management: a systematic review. Lancet Infect Dis. 2005;5(11):695–708. doi:10.1016/S1473-3099(05)70268-1.
  • Dahmana H, Mediannikov O. Mosquito-borne diseases emergence/resurgence and how to effectively control it biologically. Pathogens. 2020;9(4):310. doi:10.3390/pathogens9040310.
  • Hassan AO, Oso OV, Obeagu EI, Adeyemo AT. Malaria vaccine: prospects and challenges. Madonna Univ J Med Health Sci. 2022;2:22–40.
  • Coutinho-Abreu IV, Ramalho-Ortigao, Ramalho-Ortigao M, M. Transmission blocking vaccines to control insect-borne diseases: a review. Memórias do Inst Oswaldo Cruz. 2010;105(1):1–12. doi:10.1590/S0074-02762010000100001.
  • Laurens MB. RTS, S/AS01 vaccine (Mosquirix™): an overview. Hum Vaccines Immunother. 2020;16:480–9. doi:10.1080/21645515.2019.1669415.
  • Owino EA. World’s first malaria vaccine and its significance to malaria control in Africa. Asian Pac J Trop Med. 2022;15(2):49–52. doi:10.4103/1995-7645.338435.
  • Tully D, Griffiths CL. Dengvaxia: the world’s first vaccine for prevention of secondary dengue. Ther Adv Vaccines Immunother. 2021;9:25151355211015839. doi:10.1177/25151355211015839.
  • Salje H, Alera MT, Chua MN, Hunsawong T, Ellison D, Srikiatkhachorn A, Jarman RG, Gromowski GD, Rodriguez-Barraquer I, Cauchemez S, et al. Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection. Nature Medicine. 2021;27:1395–400. doi:10.1038/s41591-021-01392-9.
  • Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
  • Rivera L, Biswal S, Sáez-Llorens X, Reynales H, López-Medina E, Borja-Tabora C, Bravo L, Sirivichayakul C, Kosalaraksa P, Martinez Vargas L, et al. Three-year efficacy and safety of takeda’s dengue vaccine candidate (TAK-003). Clin Infect Dis. 2022;75(1):107–17. doi:10.1093/cid/ciab864.
  • Kallas EG, Precioso AR, Palacios R, Thomé B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, da Graça Salomão M, et al. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet Infect Dis. 2020;20(7):839–50. doi:10.1016/S1473-3099(20)30023-2.
  • Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino S, Zambrano B, Moureau A, Khromava A, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379(4):327–40. doi:10.1056/NEJMoa1800820.
  • Wichmann O, Vannice K, Asturias EJ, de Albuquerque Luna EJ, Longini I, Lopez AL, Smith PG, Tissera H, Yoon I-K, Hombach J, et al. Live-attenuated tetravalent dengue vaccines: the needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. Vaccine. 2017;35(42):5535–42. doi:10.1016/j.vaccine.2017.08.066.
  • Sirivichayakul C, Barranco-Santana EA, Esquilin-Rivera I, Oh HM, Raanan M, Sariol CA, Shek LP, Simasathien S, Smith MK, Velez ID, et al. Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: a randomized, placebo-controlled phase 2 Study. J Infect Dis. 2016;213(10):1562–72. doi:10.1093/infdis/jiv762.
  • Guy B, Briand O, Lang J, Saville M, Jackson N. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine. 2015;33(50):7100–11. doi:10.1016/j.vaccine.2015.09.108.
  • Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramírez JO, Carrasquilla G, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372(2):113–23. doi:10.1056/NEJMoa1411037.
  • Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358–65. doi:10.1016/S0140-6736(14)61060-6.
  • Dayan GH, Garbes P, Noriega F, Izoton de Sadovsky AD, Rodrigues PM, Giuberti C, Dietze R. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9–16 years in Brazil. Am J Trop Med Hyg. 2013;89(6):1058–65. doi:10.4269/ajtmh.13-0304.
  • Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis. 2013;207(6):957–65. doi:10.1093/infdis/jis936.
  • Villar L, Rivera-Medina DM, Arredondo-García JL, Boaz M, Starr-Spires L, Thakur M, Zambrano B, Miranda MC, Rivas E, Dayan GH. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9–16 year olds. Pediatr Infect Dis J. 2013;32(10):1102–9. doi:10.1097/INF.0b013e31829b8022.
  • Hss AS, Koh MT, Tan KK, Chan LG, Zhou L, Bouckenooghe A, Crevat D, Hutagalung Y. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: a randomized, placebo-controlled, phase III study. Vaccine. 2013;31(49):5814–21. doi:10.1016/j.vaccine.2013.10.013.
  • Lanata CF, Andrade T, Gil AI, Terrones C, Valladolid O, Zambrano B, Saville M, Crevat D. Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine. 2012;30(41):5935–41. doi:10.1016/j.vaccine.2012.07.043.
  • Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559–67. doi:10.1016/S0140-6736(12)61428-7.
  • Tran N, Luong C, Vu T, Forrat R, Lang J, Vu Q, Bouckenooghe A, Wartel TA. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin. 2012;3:1–8.
  • Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine. 2011;29(42):7251–60. doi:10.1016/j.vaccine.2011.07.020.
  • Datoo MS, Natama HM, Somé A, Bellamy D, Traoré O, Rouamba T, Tahita MC, Ido NFA, Yameogo P, Valia D, et al. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years’ follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. Lancet Infect Dis. 2022;22(12):1728–36. doi:10.1016/S1473-3099(22)00442-X.
  • Datoo MS, Natama MH, Somé A, Traoré O, Rouamba T, Bellamy D, Yameogo P, Valia D, Tegneri M, Ouedraogo F, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. 2021;397(10287):1809–18. doi:10.1016/S0140-6736(21)00943-0.
  • Sirima SB, Mordmüller B, Milligan P, Ngoa UA, Kironde F, Atuguba F, Tiono AB, Issifou S, Kaddumukasa M, Bangre O, et al. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children. Vaccine. 2016;34(38):4536–42. doi:10.1016/j.vaccine.2016.07.041.
  • Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, Lievens M, Abdulla S, Adjei S, Agbenyega T, et al. Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine. N Engl J Med. 2015;373(21):2025–37. doi:10.1056/NEJMoa1505819.
  • RTS, S Clinical Trials Partnership. Efficacy, Safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31–45.
  • The Rts SCTP. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLOS Med. 2014;11(7):e1001685. doi:10.1371/journal.pmed.1001685.
  • Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, Pinder M, Gilbert SC, Walraven G, Greenwood BM, et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLOS Med. 2004;1(2):e33. doi:10.1371/journal.pmed.0010033.
  • Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, Lievens M, Leboulleux D, Njuguna P, Peshu N, et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med. 2013;368(12):1111–20. doi:10.1056/NEJMoa1207564.
  • RTS, S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367(24):2284–95. doi:10.1056/NEJMoa1208394.
  • Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang T, Gould J, Dubois M-C, Jongert E, et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis. 2011;11(2):102–9. doi:10.1016/S1473-3099(10)70262-0.
  • Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, Owusu R, Shomari M, Leach A, Jongert E,et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis. 2011;11(10):741–9. doi:10.1016/S1473-3099(11)70100-1.
  • Leach A, Vekemans J, Lievens M, Ofori-Anyinam O, Cahill C, Owusu-Agyei S, Abdulla S, Macete E, Njuguna P, Savarese B, et al. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J. 2011;10(1):224. doi:10.1186/1475-2875-10-224.
  • Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011;365:1863–75.
  • Guinovart C, Aponte JJ, Sacarlal J, Aide P, Leach A, Bassat Q, Macete E, Dobaño C, Lievens M, Loucq C, et al. Insights into long-lasting protection induced by RTS, S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children. PLOS ONE. 2009;4(4):e5165. doi:10.1371/journal.pone.0005165.
  • Sacarlal J, Aide P, Aponte JJ, Renom M, Leach A, Mandomando I, Lievens M, Bassat Q, Lafuente S, Macete E, et al. Long-term safety and efficacy of the RTS, S/AS02A malaria vaccine in Mozambican children. J Infect Dis. 2009;200(3):329–36. doi:10.1086/600119.
  • Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen R, Debebe Z, Pinelis E, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200(3):337–46. doi:10.1086/600120.
  • Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois M-C, et al. Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med. 2008;359(24):2521–32. doi:10.1056/NEJMoa0807381.
  • Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C, Omari S, Urassa A, Mshinda H, Jumanne A, et al. Safety and immunogenicity of RTS, S/AS02D malaria vaccine in infants. N Engl J Med. 2008;359(24):2533–44. doi:10.1056/NEJMoa0807773.
  • Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG Jr, Hall T, Wellde BT, White K, Sun P, Schwenk R, et al. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. Vaccine. 2007;25(29):5359–66. doi:10.1016/j.vaccine.2007.05.005.
  • Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, Manaca MN, Lafuente S, Barbosa A, Leach A, et al. Safety of the RTS, S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet. 2007;370(9598):1543–51. doi:10.1016/S0140-6736(07)61542-6.
  • Bojang KA, Milligan PJM, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, et al. Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomised trial. Lancet. 2001;358(9297):1927–34. doi:10.1016/S0140-6736(01)06957-4.
  • Camacho LA, de Aguiar SG, Freire Mda S, Leal Mda L, Do Nascimento JP, Iguchi T, Lozana JA, Farias RH. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. Rev Saude Publica. 2005;39(3):413–20. doi:10.1590/S0034-89102005000300012.
  • Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, Shope RE, Thomas N, Schrader R, Furby D, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002;66(5):533–41. doi:10.4269/ajtmh.2002.66.533.
  • McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2020;12(1):55–61. doi:10.1002/jrsm.1411.
  • Hartling L, Ospina M, Liang Y, Dryden DM, Hooton N, Seida JK, Klassen TP. Risk of bias versus quality assessment of randomised controlled trials: cross sectional study. BMJ. 2009;339(oct19 1):4012–4012. doi:10.1136/bmj.b4012.
  • Hartling L, Ospina M, Liang Y, Dryden DM, Hooton N, Seida JK, Klassen TP. Risk of bias versus quality assessment of randomised controlled trials: cross sectional study. BMJ. 2009;339(oct19 1):b4012. doi:10.1136/bmj.b4012.
  • Pathak VK, Mohan M. A notorious vector-borne disease: dengue fever, its evolution as public health threat. J Family Med Prim Care. 2019;8(10):3125. doi:10.4103/jfmpc.jfmpc_716_19.
  • Organization W. Global strategy for dengue prevention and control, 2012–2020 WHO, Geneva 2012; 2012.
  • López-Medina E, Biswal S, Saez-Llorens X, Borja-Tabora C, Bravo L, Sirivichayakul C, Vargas LM, Alera MT, Velásquez H, Reynales H, et al. Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination. J Infect Dis. 2020;225(9):1521–32. doi:10.1093/infdis/jiaa761.
  • White LJ, Young EF, Stoops MJ, Henein SR, Adams EC, Baric RS, de Silva AM. Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003). PLOS Negl Trop Dis. 2021;15(3):e0009258. doi:10.1371/journal.pntd.0009258.
  • Tricou V, Folschweiller N, Lloyd E, Rauscher M, Biswal S. Efficacy and safety of Takeda’s tetravalent dengue vaccine candidate (TAK-003) after 4.5 years of follow-up. In: 44th ICMM World Congress on Military Medicine. Vol. 11. 2022. p. 5–9.
  • Durbin AP. Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005. Curr Opin Virol. 2020;43:79–87. doi:10.1016/j.coviro.2020.09.005.
  • Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis. 2015;212(5):702–10. doi:10.1093/infdis/jiv082.
  • Silveira CG, Magnani DM, Costa PR, Avelino-SilvaI V, Ricciardi MJ, Timenetsky M. Plasmablast expansion following the tetravalent, live-attenuated dengue vaccine Butantan-DV in DENV-Naïve and DENV-exposed individuals in a Brazilian cohort. Front Immunol. 2022;13:908398. doi:10.3389/fimmu.2022.908398.
  • Thomas SJ, Yoon IK. A review of Dengvaxia®: development to deployment. Hum Vaccin Immunother. 2019;15(10):2295–314. doi:10.1080/21645515.2019.1658503.
  • Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011;29(42):7229–41. doi:10.1016/j.vaccine.2011.06.094.
  • Guy B, Saville M, Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin. 2010;6(9):696–705. doi:10.4161/hv.6.9.12739.
  • Dayan GH, Langevin E, Forrat R, Zambrano B, Noriega F, Frago C, Bouckenooghe A, Machabert T, Savarino S, DiazGranados CA, et al. Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus. Vaccine. 2020;38(41):6472–7. doi:10.1016/j.vaccine.2020.07.056.
  • Malisheni M, Khaiboullina SF, Rizvanov AA, Takah N, Murewanhema G, Bates M. Clinical efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (CYD-TDV) in children: a systematic review with meta-analysis. Front Immunol. 2017;8:863. doi:10.3389/fimmu.2017.00863.
  • Mizumoto K, Ejima K, Yamamoto T, Nishiura H. On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling. J Vector Borne Dis. 2014;51:153.
  • Endy TP, Yoon I-K, Mammen MP. Current topics in microbiology and immunology. In: Dengue virus. Vol. 338. 2010. p. 1–13.
  • Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol. 2016;14(1):45–54. doi:10.1038/nrmicro.2015.2.
  • Tran NH, Chansinghakul D, Chong CY, Low CY, Shek LP, Luong CQ, Frago C, Wartel TA, Sun S, Skipetrova A, et al. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials. Hum Vaccines Immunother. 2019;15(10):2315–27. doi:10.1080/21645515.2019.1578595.
  • Bonam SR, Rénia L, Tadepalli G, Bayry J, Kumar HMS. Plasmodium falciparum malaria vaccines and vaccine adjuvants. Nato Vaccines. 2021;9(10):1072. doi:10.3390/vaccines9101072.
  • Rougeron V, Boundenga L, Arnathau C, Durand P, Renaud F, Prugnolle F. A population genetic perspective on the origin, spread and adaptation of the human malaria agents Plasmodium falciparum and Plasmodium vivax. FEMS Microbiol Rev. 2022;46(1):fuab047. doi:10.1093/femsre/fuab047.
  • Snow RW. Global malaria eradication and the importance of Plasmodium falciparum epidemiology in Africa. BMC Med. 2015;13(1):23. doi:10.1186/s12916-014-0254-7.
  • Garcia LS. Malaria. Clin Lab Med. 2010;30(1):93–129. doi:10.1016/j.cll.2009.10.001.
  • Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H, Madsen SM, Druilhe P. A Plasmodium falciparum GLURP–MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine. 2004;22(9–10):1188–98. doi:10.1016/j.vaccine.2003.09.017.
  • Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, Druilhe P, Petri WA. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun. 2000;68(5):2617–20. doi:10.1128/IAI.68.5.2617-2620.2000.
  • Roussilhon C, Oeuvray C, Müller-Graf C, Tall A, Rogier C, Trape JF, Theisen M, Balde A, Pérignon J-L, Druilhe P, et al. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med. 2007;4(11):e320. doi:10.1371/journal.pmed.0040320.
  • Jepsen MP, Jogdand PS, Singh SK, Esen M, Christiansen M, Issifou S, Hounkpatin AB, Ateba-Ngoa U, Kremsner PG, Dziegiel MH, et al. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas. J Infect Dis. 2013;208(3):479–88. doi:10.1093/infdis/jit185.
  • Esen M, Kremsner PG, Schleucher R, Gässler M, Imoukhuede EB, Imbault N, Leroy O, Jepsen S, Knudsen BW, Schumm M, et al. Safety and immunogenicity of GMZ2 — a MSP3–GLURP fusion protein malaria vaccine candidate. Vaccine. 2009;27(49):6862–8. doi:10.1016/j.vaccine.2009.09.011.
  • Mordmüller B, Szywon K, Greutelaers B, Esen M, Mewono L, Treut C, Mürbeth RE, Chilengi R, Noor R, Kilama WL, et al. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon. Vaccine. 2010;28(41):6698–703. doi:10.1016/j.vaccine.2010.07.085.
  • Bélard S, Issifou S, Hounkpatin AB, Schaumburg F, Ngoa UA, Esen M, Fendel R, de Salazar PM, Mürbeth RE, Milligan P, et al. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. PLOS ONE. 2011;6(7):e22525. doi:10.1371/journal.pone.0022525.
  • Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci. 1973;266(3):169–77. doi:10.1097/00000441-197309000-00002.
  • Vreden SG, Verhave JP, Oettinger T, Sauerwein RW, Meuwissen JH. Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen. Am J Trop Med Hyg. 1991;45(5):533–8. doi:10.4269/ajtmh.1991.45.533.
  • Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garçon N, Krzych U, Marchand M, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 1997;336(2):86–91. doi:10.1056/NEJM199701093360202.
  • Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler M, et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis. 2001;183(4):640–7. doi:10.1086/318534.
  • Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200(3):337–46. doi:10.1086/600120.
  • Polhemus ME, Remich SA, Ogutu BR, Waitumbi JN, Otieno L, Apollo S, Cummings JF, Kester KE, Ockenhouse CF, Stewart A, et al. Evaluation of RTS, S/AS02A and RTS, S/AS01B adults in high malar transmission area. PLOS ONE. 2009;4(7):e6465. doi:10.1371/journal.pone.0006465.
  • Penny MA, Verity R, Bever CA, Sauboin C, Galactionova K, Flasche S, White MT, Wenger EA, Van de Velde N, Pemberton-Ross P, et al. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2016;387(10016):367–75. doi:10.1016/S0140-6736(15)00725-4.
  • Otieno L, Oneko M, Otieno W, Abuodha J, Owino E, Odero C, Mendoza YG, Andagalu B, Awino N, Ivinson K, et al. Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial. Lancet Infect Dis. 2016;16(10):1134–44. doi:10.1016/S1473-3099(16)30161-X.
  • Lell B, Agnandji S, von Glasenapp I, Haertle S, Oyakhiromen S, Issifou S, Vekemans J, Leach A, Lievens M, Dubois M-C, et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLOS ONE. 2009;4(10):e7611. doi:10.1371/journal.pone.0007611.
  • Owusu-Agyei S, Ansong D, Asante K, Kwarteng Owusu S, Owusu R, Wireko Brobby NA, Dosoo D, Osei Akoto A, Osei-Kwakye K, Adjei EA, et al. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLOS ONE. 2009;4(10):e7302. doi:10.1371/journal.pone.0007302.
  • Pallikkuth S, Chaudhury S, Lu P, Pan L, Jongert E, Wille-Reece U, Pahwa S. A delayed fractionated dose RTS, S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses. Elife. 2020;9:e51889. doi:10.7554/eLife.51889.
  • Garçon N, Di Pasquale A. From discovery to licensure, the Adjuvant System story. Hum Vaccines Immunother. 2017;13(1):19–33. doi:10.1080/21645515.2016.1225635.
  • Regules JA, Cummings JF, Ockenhouse CF. The RTS, S vaccine candidate for malaria. Expert Rev Vaccines. 2011;10(5):589–99. doi:10.1586/erv.11.57.
  • Stoute J, Kester K, Krzych U, Wellde B, Hall T, White K, Glenn G, Ockenhouse CF, Garcon N, Schwenk R, et al. Long-term efficacy and immune responses following immunization with the RTS, S malaria vaccine. J Infect Dis. 1998;178(4):1139–44. doi:10.1086/515657.
  • Leroux-Roels G, Leroux-Roels I, Clement F, Ofori-Anyinam O, Lievens M, Jongert E, Moris P, Ballou WR, Cohen J. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults. Hum Vaccin Immunother. 2014;10(8):2211–9. doi:10.4161/hv.29375.
  • Garçon N, Heppner DG, Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines. 2003;2:231–8. doi:10.1586/14760584.2.2.231.
  • Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci Rep. 2017;7(1):46621. doi:10.1038/srep46621.
  • Venkatraman N, Tiono AB, Bowyer G, Powlson J, Collins KA, Coulibaly S, Datoo M, Silman D, Ouedraogo A, Nébié I, et al. Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers. medRxiv. 2019:19009282.
  • Krishna S. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLOS Med. 2014;11(7):e1001685. doi:10.1371/journal.pmed.1001685.
  • Geneva. WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization; 2023.
  • Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801. doi:10.1016/j.cell.2006.02.015.
  • Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G, Bliss C, Hodgson SH, Njuguna P, Viebig NK, et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med. 2015;7(286):2865–5. doi:10.1126/scitranslmed.aaa2373.
  • Afolabi MO, Tiono AB, Adetifa UJ, Yaro JB, Drammeh A, Nébié I, Bliss C, Hodgson SH, Anagnostou NA, Sanou GS, et al. Safety and immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants. Mol Ther. 2016;24(8):1470–7. doi:10.1038/mt.2016.83.
  • Bejon P, Mwacharo J, Kai O, Todryk S, Keating S, Lowe B, Lang T, Mwangi TW, Gilbert SC, Peshu N, et al. The induction and persistence of T cell IFN-γ responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. J Immunol. 2007;179(6):4193–201. doi:10.4049/jimmunol.179.6.4193.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.